Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To assess the risk of myocardial infarction (MI), stroke or death in new users of IVT aflibercept versus new users of IVT ranibizumab in real-world practice

Next Previous
Trial Profile

To assess the risk of myocardial infarction (MI), stroke or death in new users of IVT aflibercept versus new users of IVT ranibizumab in real-world practice

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
  • Indications Age-related macular degeneration; Diabetic macular oedema
  • Focus Adverse reactions

Most Recent Events

  • 15 Sep 2021 New trial record
  • 25 Aug 2021 Results presented at the 37th International Conference on Pharmacoepidemiology and Therapeutic Risk Management

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top